Lucknow, Aug 13 (Ians) The Csir-Central Drug Research Institute (Cdri) in Lucknow has introduced an innovative contraceptive named ‘Levormeloxifene’.
The breakthrough contraceptive is notably more effective to the human body with its reduced dose and chemical burden compared to existing market options.
Levormeloxifene is a modernised version of the 1990s ‘Saheli’ pill, initially developed by Cdri. Once a staple during the 1990s, Saheli, also known as ‘Chaya’ under the National Family Planning programme, has now evolved into Levormeloxifene.
Radha Rangarajan, Director of Csir-cdri, explained, “The core objective behind this contraceptive’s development was to minimise the chemical content, particularly crucial for women in their reproductive phase who predominantly consume such tablets.”
Rangarajan elaborated, “The compound ormeloxifene within Saheli comprises two enantiomers, dextro-ormeloxifene, and levo-ormeloxifene (levormeloxifene). Extensive preclinical studies have indicated higher efficacy of the levo counterpart, levormeloxifene. This research solely focuses on testing the levo model as a contraceptive, thereby reducing...
The breakthrough contraceptive is notably more effective to the human body with its reduced dose and chemical burden compared to existing market options.
Levormeloxifene is a modernised version of the 1990s ‘Saheli’ pill, initially developed by Cdri. Once a staple during the 1990s, Saheli, also known as ‘Chaya’ under the National Family Planning programme, has now evolved into Levormeloxifene.
Radha Rangarajan, Director of Csir-cdri, explained, “The core objective behind this contraceptive’s development was to minimise the chemical content, particularly crucial for women in their reproductive phase who predominantly consume such tablets.”
Rangarajan elaborated, “The compound ormeloxifene within Saheli comprises two enantiomers, dextro-ormeloxifene, and levo-ormeloxifene (levormeloxifene). Extensive preclinical studies have indicated higher efficacy of the levo counterpart, levormeloxifene. This research solely focuses on testing the levo model as a contraceptive, thereby reducing...
- 8/13/2023
- by Agency News Desk
- GlamSham
IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news articles, Tweets, and blog posts do not represent IMDb's opinions nor can we guarantee that the reporting therein is completely factual. Please visit the source responsible for the item in question to report any concerns you may have regarding content or accuracy.